212 related articles for article (PubMed ID: 9224970)
21. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
22. [Tumor-induced immunosuppression].
Paul S; Calmels B; Régulier E
Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
[TBL] [Abstract][Full Text] [Related]
23. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
24. The importance of 'Mechnikov's thorn' for an improved understanding of 21st century medicine and immunology: a view from the eye.
McGonagle D; Georgouli T
Scand J Immunol; 2008 Aug; 68(2):129-39. PubMed ID: 18510591
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4.
Hall BM; Fava L; Chen J; Plain KM; Boyd RA; Spicer ST; Berger MF
J Immunol; 1998 Nov; 161(10):5147-56. PubMed ID: 9820484
[TBL] [Abstract][Full Text] [Related]
26. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
27. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.
Majlessi L; Bordenave G
Arch Immunol Ther Exp (Warsz); 2001; 49(6):407-15. PubMed ID: 11814234
[TBL] [Abstract][Full Text] [Related]
29. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.
Pellegrini P; Berghella AM; Contasta I; Adorno D
Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032
[TBL] [Abstract][Full Text] [Related]
30. The immunologic consequences of laparoscopy in oncology.
Carter JJ; Whelan RL
Surg Oncol Clin N Am; 2001 Jul; 10(3):655-77. PubMed ID: 11685934
[TBL] [Abstract][Full Text] [Related]
31. A fresh look at tumor immunosurveillance and immunotherapy.
Smyth MJ; Godfrey DI; Trapani JA
Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
[TBL] [Abstract][Full Text] [Related]
32. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
33. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
34. Surveillance against tumors--is it mainly immunological?
Klein G; Klein E
Immunol Lett; 2005 Aug; 100(1):29-33. PubMed ID: 16129497
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
36. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
37. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
38. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
39. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
40. Cancer and immune response: old and new evidence for future challenges.
de la Cruz-Merino L; Grande-Pulido E; Albero-Tamarit A; Codes-Manuel de Villena ME
Oncologist; 2008 Dec; 13(12):1246-54. PubMed ID: 19056856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
